

Supplementary Figure 1. Survival analysis of PTEN and oxidative stress regulatory factors in breast cancer patients.

(A)&(B) Optimal cutoffcalculating BRCA patients data including total survival and PTEN expression were collected from TCGA-BRCA database, and optimal cutoff was calculated by R language survey package. The cutpoint was 12.93. (C) Overall survival analysis of BRCA patients with different level of oxidative stress response regulation. BRCA patientsd data from TCGA-BRCA database was collected and performed enrichment analyses with "positive_regulation_of_response_to_oxidative_stress"(GO:1902884) from the GSEA database. Kaplan-Meier survival analysis was performed on the classified groups: positive_regulation_high and positive_ regulation_low. (D) Kaplan-Meier survival analysis was performed on the classified groups: negative_regulation_high and negative_ regulation_low.((GO:1902883)) Same as (C). (E) Authentication of BMDMs (BMC on d7) using flow cytometry.

Supplementary Figure 2



sFig. 2 Mechanisms of SGs impairing anti-tumor immunity of PTEN deficient BMDMs.LPS (100 ng/mL) was treated to the two groups of BMDM for 4 hours for activation, and the UT group was the untreated control group. The Ars group was induced by sodium arsenite at 90 μ M for 1 hour. (**A**). The levels of IL-6, TNF, and MCP-1 in the cell supernatant were detected using the CBA method simultaneously. The statistical method was mean \pm standard deviation; n = 3 independent experiments,double-tailed student T-test, and ns had no statistical significance. (**B**) Gating strategies sorting MHC-II positive cells. (**C and D**)The FITC-MHC -II antibody was used to mark each group of BMDM, and the percentage of positive cells in each group was calculated. (**E**) Relative mRNA level of several canonical phagocyte-related receptors on macrophages.Cells were harvested with or without SGs induction. (**F**) The IDRs prediction of MYH9 by the D2P2 database (Database of Disordered Protein Predictions).The target region were showed in red frame and highlighted in bright green. (**G**) Intracellular ATP level in 4T1 cells. 2DG was given at 5 mM for 1 hour. means \pm SDs; n = 10 holes of 3 independent experiments, p value was determined by two-tailed unpaired Student's t test with multiple comparisons test. (**H**) Fluorescence staining of cytoskeleton and stress granules.Actin-Tracker Green (green) was used to label myosin filaments F-actin, and Alexa Fluor®594 (red) was used to label G3BP1 as a representative of core proteins of stress granules. The dotted accumulation of G3BP1 represented the formed stress granules.

| Grade(score) | Description | |
|--------------|--|--|
| 1 | no change or some alteration to individual malignant cells but no reduction in overall cellularity | |
| 2 | a minor loss of tumour cells but overall cellularity still high; up to 30% loss | |
| 3 | an estimated 30% - 90% reduction in tumour cells | |
| 4 | a marked disappearance of tumour cells such that only small clusters or widely dispersed individual cells remain; more than 90% loss of tumour cells | |
| 5 | no malignant cells identifiable in sections from the site of the tumour; only vascular fibroelastotic stroma remains often containing macrophages. Ductal carcinoma in situ (DCIS) may be present. | |

Miller-Payne (MP) scoring system

| Gene | Direction | Sequence (5'-3') |
|------------------|-----------|-------------------------|
| Actin | forward | GGCTGTATTCCCCTCCATCG |
| | reverse | CCAGTTGGTAACAATGCCATGT |
| PTEN | forward | TGGATTCGACTTAGACTTGACCT |
| | reverse | GCGGTGTCATAATGTCTCTCAG |
| E.D.I | forward | AGGTTCCTCAATGCCAAGTGA |
| Гсүк 1 | reverse | GCGACCTCCGAATCTGAAGA |
| E D III | forward | ATGGGAATCCTGCCGTTCCTA |
| гсүк пб | reverse | CCGTGAGAACACATGGACAGT |
| FcγR III | forward | CAGAATGCACACTCTGGAAGC |
| | reverse | GGGTCCCTTCGCACATCAG |
| | forward | ATGTGGCAGCTACTACTACCA |
| Γ ΟγΚ Ιν | reverse | ACCCACTTGGGGTCTAGGTTC |
| | forward | AGTCACGGGGAAAGAACTGAA |
| SIRPa | reverse | CGGCTTTGCCTACTCCTCTG |
| OLAME7 | forward | AGAACGCAGACTATGACACAATC |
| SLAMF / | reverse | AGGGAGCTGGGACTCTTTACC |
| DTENI 1 ave | forward | CTCCTCTACTCCATTCTTCCC |
| PTEN loxp | reverse | ACTCCCACCAATGAACAAAC |
| | Common | CTTGGGCTGCCAGAATTTCTC |
| Lyz2 cre | Wt | TTACAGTCGGCCAGGCTGAC |
| | Mut | CCCAGAAATGCCAGATTACG |
| | forward | ACACATAATCCCAGCACTAGG |
| HAL1-primerA | reverse | ACACATAATCCCAGCACTAGG |
| TIAL 1 mains anD | forward | GGCAGGATCCTACTTCAAGTTC |
| 11AL1-primerB | reverse | TGAAGATTGATCACGTTGGGG |
| | forward | TGGCACATACACATAATCCCA |
| 11AL1-primerC | reverse | CAGCATGCAAGGGATGGA |

Primers for PCR and qPCR

Original file of Western Blot

Fig.2D



•

β-actin





P-eIf2α

Ars+



PTEN



eIf2α

eIf2α



Fig.2E



Fig.3E





β-actin

PTEN

EGR1